{"id":"vigabatrin-tablets","_chembl":null,"_dailymed":null,"_scrapedAt":"2026-03-28T05:36:13.110Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T10:09:18.151673+00:00","fieldsConflicting":0,"overallConfidence":0.95},"trialDetails":[{"nctId":"NCT04062890","phase":"PHASE2","title":"Inhibiting GABA Transaminase to Relieve Obesity Induced Hyperinsulinemia and Insulin Resistance","status":"WITHDRAWN","sponsor":"University of Arizona","startDate":"2030-04-15","conditions":"Hyperinsulinism, Insulin Resistance, Insulin Sensitivity","enrollment":""},{"nctId":"NCT04302116","phase":"NA","title":"Vigabatrin With High Dose Prednisolone Combination Therapy vs Vigabatrin Alone for Infantile Spasm","status":"RECRUITING","sponsor":"Kullasate Sakpichaisakul","startDate":"2020-05-18","conditions":"Infantile Spasm, West Syndrome","enrollment":250},{"nctId":"NCT00730522","phase":"PHASE2","title":"Safety and Efficacy Study of Vigabatrin to Treat Methamphetamine Dependence","status":"TERMINATED","sponsor":"Catalyst Pharmaceuticals, Inc.","startDate":"2008-07","conditions":"Methamphetamine Dependence","enrollment":55},{"nctId":"NCT04468282","phase":"PHASE1","title":"Bioequivalence Study of Vigabatrin ORPHELIA Pharma 500mg Soluble Tablets and SabrilTM 500mg Granules for Oral Administration","status":"COMPLETED","sponsor":"Orphelia Pharma","startDate":"2017-04-04","conditions":"Therapeutic Equivalency","enrollment":20},{"nctId":"NCT02220114","phase":"NA","title":"Acceptability Study of a New Paediatric Form of Vigabatrin in Infants and Children With Infantile Spasms or Pharmacoresistant Partial Epilepsy","status":"COMPLETED","sponsor":"Orphelia Pharma","startDate":"2014-05","conditions":"Infantile Spasms","enrollment":38},{"nctId":"NCT01585207","phase":"PHASE1, PHASE2","title":"Proof-of-Concept Safety Study of CPP-109 (Vigabatrin) for Treatment Refractory Tourette's Disorder","status":"COMPLETED","sponsor":"Barbara J. Coffey","startDate":"2012-07","conditions":"Tourette's Disorder","enrollment":4},{"nctId":"NCT01278173","phase":"PHASE4","title":"A Study of the Structure and Function of the Retina in Adult Patients With Refractory Complex Partial Seizures Treated With Vigabatrin (Sabril®)","status":"COMPLETED","sponsor":"Lundbeck LLC","startDate":"2010-12","conditions":"Adult Refractory Complex Partial Seizures","enrollment":65},{"nctId":"NCT01281202","phase":"PHASE2, PHASE3","title":"Vigabatrin for the Treatment of Cocaine Dependency","status":"COMPLETED","sponsor":"Catalyst Pharmaceuticals, Inc.","startDate":"2011-01","conditions":"Cocaine Addiction, Cocaine Dependence","enrollment":207},{"nctId":"NCT00611130","phase":"PHASE2","title":"Vigabatrin for Treatment of Cocaine Dependence","status":"COMPLETED","sponsor":"Catalyst Pharmaceuticals, Inc.","startDate":"2008-01","conditions":"Cocaine Dependence","enrollment":186}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Sabril"],"phase":"phase_1","status":"active","brandName":"Vigabatrin Tablets","genericName":"Vigabatrin Tablets","companyName":"Kullasate Sakpichaisakul","companyId":"kullasate-sakpichaisakul","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":5,"visitCount":1,"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T10:09:18.151673+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}